Braveheart Bio Stock (NASDAQ:BRVE)
Previous Close
$19.09
52W Range
$17.86 - $32.00
50D Avg
$25.42
200D Avg
$25.42
Market Cap
$1.41B
Avg Vol (3M)
$551.79K
Beta
-
Div Yield
-
BRVE Company Profile
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.